Uniplan Investment Counsel’s Fortress Biotech 9.375% Series A Preferred Stock FBIOP Stock Holding History

Uniplan Investment Counsel’s Portfolio FBIOP Stock Details FBIOP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-149,327	Closed	-$3.58M	–	125
2022 Q1	$3.58M	Sell	149,327 -1,037	-0.7%	-$25.3K	0.21%	87
2021 Q4	$3.89M	Sell	150,364 -9,747	-6%	-$253K	0.22%	79
2021 Q3	$4.15M	Sell	160,111 -4,720	-3%	-$122K	0.26%	73
2021 Q2	$4.28M	Sell	164,831 -5,949	-3%	-$152K	0.25%	77
2021 Q1	$4.06M	Sell	170,780 -12,906	-7%	-$283K	0.26%	71
2020 Q4	$3.56M	Sell	183,686 -15,189	-8%	-$285K	0.24%	78
2020 Q3	$3.75M	Sell	198,875 -13,368	-6%	-$246K	0.26%	66
2020 Q2	$3.79M	Buy	212,243 +56,960	+37%	+$1.03M	0.26%	64
2020 Q1	$2.35M	Buy	+155,283	New	+$3M	0.18%	76

Other funds holding FBIOP

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Uniplan Investment Counsel's FBIOP Position: Q2 2022 in Review

Uniplan Investment Counsel sold out of Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) in Q2 2022, closing a stake of 149,327 shares — an estimated $3.58M sold.

Uniplan Investment Counsel first reported a position in FBIOP in Q1 2020 and held it in 9 quarters. The position peaked at $4.28M in Q2 2021. 1 fund tracked by Wall St. Rank holds FBIOP as of Q2 2022.

Uniplan Investment Counsel reported no remaining Fortress Biotech 9.375% Series A Preferred Stock position as of Q2 2022 after selling out during the quarter.
Uniplan Investment Counsel sold 149,327 Fortress Biotech 9.375% Series A Preferred Stock shares in Q2 2022, an estimated $3.58M.
Uniplan Investment Counsel first reported a position in Fortress Biotech 9.375% Series A Preferred Stock in Q1 2020 and held it in 9 quarters.
Uniplan Investment Counsel's Fortress Biotech 9.375% Series A Preferred Stock position peaked at $4.28M in Q2 2021.
1 fund tracked by Wall St. Rank held Fortress Biotech 9.375% Series A Preferred Stock as of Q2 2022.

Based on Uniplan Investment Counsel's 13F filing for Q2 2022, filed 15 Aug 2022.